While long-read sequencing is invaluable for characterizing AAV genomes, it lacks standardized nomenclature and metrics, which makes it difficult to analyze and interpret the data. To address this, we’ve established an AAV Working Group, partnering with academic and industry leaders to set standards aimed at driving improvements in vector design and product quality.
The AAV Working Group members are leading thinkers and doers in gene therapy, from both academia and industry. Members work with FormBio and PacBio to help shape and contribute to various AAV standards and best practice knowledge sharing.
Form offers award-winning software and AI solutions for cell and gene therapy leaders. By combining data, technology and expertise, Form’s solutions accelerate timelines from discovery to clinic by providing drug developers with rapid in silico characterization, prediction, simulation and optimization of their therapeutics.
Highly accurate PacBio HiFi sequencing allows researchers to comprehensively discover, design, and confirm their gene therapy approaches.
